Details:

Alternative Title:
Emerg Infect Dis
Personal Author:
Prosser, Lisa A.; Bridges, Carolyn Buxton; Uyeki, Timothy M.; Hinrichsen, Virginia L.; Meltzer, Martin I.; ... More +
Prosser, Lisa A.; Bridges, Carolyn Buxton; Uyeki, Timothy M.; Hinrichsen, Virginia L.; Meltzer, Martin I.; Molinari, Noelle-Angelique M.; Schwartz, Benjamin; Thompson, William W.; Fukuda, Keiji; Lieu, Tracy A.; Less -
Description:
We estimated cost-effectiveness of annually vaccinating children not at high risk with inactivated influenza vaccine (IIV) to range from US $12,000 per quality-adjusted life year (QALY) saved for children ages 6-23 months to $119,000 per QALY saved for children ages 12-17 years. For children at high risk (preexisting medical conditions) ages 6-35 months, vaccination with IIV was cost saving. For children at high risk ages 3-17 years, vaccination cost $1,000-$10,000 per QALY. Among children notat high risk ages 5-17 years, live, attenuated influenza vaccine had a similar cost-effectiveness as IIV. Risk status was more important than age in determining the economic effects of annual vaccination, and vaccination was less cost-effective as the child's age increased. Thus, routine vaccination of all children is likely less cost-effective than vaccination of all children ages 6-23 months plus all other children at high risk.
Subject:
[+]
Adolescent
Child
Child, Preschool
Cost-Benefit Analysis
Humans
Infant
Influenza Vaccines
Mass Vaccination
Quality Of Life
Research
Sensitivity And Specificity
Vaccines, Inactivated

Source:
Emerg Infect Dis. 12(10):1548-1558.;
Document Type:
Journal Article;
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:d557978e2a303825e99951d21f312fa00d35f958c1ad13cd29ac98bd0d97c7e5
File Type:

Supporting Files

• 	05-1015-M1.jpg	jpeg
  	05-1015.nxml	txt
  	license.txt	txt
  	05-1015-F1.gif	gif
  	05-1015-F1.jpg	jpeg
  	05-1015-F2.gif	gif
  	05-1015-F2.jpg	jpeg
  	05-1015-F3.gif	gif
  	05-1015-F3.jpg	jpeg
  	05-1015-FA1.gif	gif
  	05-1015-FA1.jpg	jpeg

More +